On July 10, Tempus AI fell 5.01% in regular trading, trading at $58.37/share, with turnover of $66.04 million. The decline reflects the continued fallout from multiple negative catalysts that surfaced earlier this week.

On the news front, Biovica International AB announced the termination of its collaboration agreement with Tempus AI, explicitly stating that the partnership failed to result in any product commercialization or generate any revenue. Additionally, CEO Eric P. Lefkofsky recently sold approximately 126,250 shares of Class A common stock through a pre-arranged 10b5-1 plan at prices ranging from $54.82 to $59.59 per share. The combination of the partnership dissolution and insider selling has intensified bearish sentiment.

Further compounding pressure, Freedom Capital Markets recently initiated coverage on Tempus AI with a Hold rating and a $59 price target. The stock has now fallen below that target level, reinforcing investor caution ahead of the company's second-quarter earnings report scheduled for July 30.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)